61/100B51.365
USD
-0.33
(-0.64%)
Market Closed
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.23Revenue estimate 1.25B
Q4 FY2026 · Earnings report
EPS estimate 0.23Revenue estimate 1.25B
Genmab A price to sales (P/S) ratioWhat is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
Genmab A/S ADS's P/S ratio is 7.37: its market cap of 31.67B USD over revenue of 4.30B USD in the last twelve months.
- Today
- 7.37
- Average, 5 years
- 2.13
- Low, 5 years
- 0.70
- High, 5 years
- 8.51
P/S ratio = market cap ÷ revenue (last 12 months) = 31.67B ÷ 4.30B = 7.37
Each day's market cap over the revenue of the last four quarters reported by that day.
P/S ratio by year and by quarter
| Fiscal year | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Today | 7.37 | 31.67B | 4.30B | |
| FY2025 | 31 Dec 2025 | 5.14 | 19.14B | 3.72B |
| FY2024 | 31 Dec 2024 | 4.51 | 97.16B | 21.53B |
| FY2023 | 31 Dec 2023 | 8.60 | 141.71B | 16.47B |
| FY2022 | 31 Dec 2022 | 13.27 | 192.46B | 14.51B |
| FY2021 | 31 Dec 2021 | 20.09 | 169.12B | 8.42B |
| FY2020 | 31 Dec 2020 | 15.96 | 161.42B | 10.11B |
| FY2019 | 31 Dec 2019 | 17.46 | 93.69B | 5.37B |
| FY2018 | 31 Dec 2018 | 21.73 | 65.75B | 3.03B |
| FY2017 | 31 Dec 2017 | 26.45 | 62.57B | 2.37B |
| FY2016 | 31 Dec 2016 | 38.63 | 70.16B | 1.82B |
| FY2015 | 31 Dec 2015 | 47.52 | 53.84B | 1.13B |
| FY2014 | 31 Dec 2014 | 23.88 | 20.31B | 850.39M |
| FY2013 | 31 Dec 2013 | 16.25 | 10.78B | 663.57M |
| FY2012 | 31 Dec 2012 | 7.52 | 3.64B | 484.64M |
| FY2011 | 31 Dec 2011 | 4.80 | 1.68B | 350.94M |
| FY2010 | 31 Dec 2010 | 5.80 | 3.38B | 582.08M |
| FY2009 | 31 Dec 2009 | 6.01 | 3.52B | 586.08M |
| FY2008 | 31 Dec 2008 | 12.95 | 8.97B | 692.30M |
| FY2007 | 31 Dec 2007 | 15.98 | 8.46B | 529.54M |
| FY2006 | 31 Dec 2006 | 61.17 | 8.29B | 135.55M |
| FY2005 | 31 Dec 2005 | 75.33 | 7.42B | 98.51M |
| FY2004 | 31 Dec 2004 | 1,333.80 | 5.47B | 4.10M |
| FY2003 | 31 Dec 2003 | 74.48 | 5.09B | 68.33M |
| FY2002 | 31 Dec 2002 | — | 5.24B | 0.00 |
| Quarter | Period ending | P/S ratio | Market cap | Revenue |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 5.09 | 21.86B | 4.30B |
| Q2 FY2026 | 30 Jun 2026 | 4.08 | 16.85B | 4.13B |
| Q1 FY2026 | 31 Mar 2026 | 4.22 | 16.47B | 3.90B |
| Q4 FY2025 | 31 Dec 2025 | 6.11 | 18.98B | 3.11B |
| Q3 FY2025 | 30 Sept 2025 | 2.22 | 18.89B | 8.49B |
| Q2 FY2025 | 30 Jun 2025 | 0.98 | 12.76B | 13.01B |
| Q1 FY2025 | 31 Mar 2025 | 0.71 | 12.48B | 17.49B |
| Q4 FY2024 | 31 Dec 2024 | 5.36 | 96.44B | 17.99B |
| Q3 FY2024 | 30 Sept 2024 | 6.53 | 105.90B | 16.22B |
| Q2 FY2024 | 30 Jun 2024 | 7.26 | 111.84B | 15.40B |
| Q1 FY2024 | 31 Mar 2024 | 9.69 | 137.24B | 14.16B |
| Q4 FY2023 | 31 Dec 2023 | 8.56 | 140.40B | 16.39B |
| Q3 FY2023 | 30 Sept 2023 | 9.64 | 162.43B | 16.85B |
| Q2 FY2023 | 30 Jun 2023 | 10.43 | 169.22B | 16.23B |
| Q1 FY2023 | 31 Mar 2023 | 11.15 | 169.73B | 15.22B |
| Q4 FY2022 | 31 Dec 2022 | 13.25 | 192.16B | 14.51B |
| Q3 FY2022 | 30 Sept 2022 | 13.27 | 159.12B | 11.99B |
| Q2 FY2022 | 30 Jun 2022 | 14.79 | 150.98B | 10.21B |
| Q1 FY2022 | 31 Mar 2022 | 17.72 | 159.85B | 9.02B |
| Q4 FY2021 | 31 Dec 2021 | 19.94 | 169.15B | 8.48B |
| Q3 FY2021 | 30 Sept 2021 | 23.21 | 183.56B | 7.91B |
| Q2 FY2021 | 30 Jun 2021 | 22.87 | 167.43B | 7.32B |
| Q1 FY2021 | 31 Mar 2021 | 12.60 | 136.13B | 10.80B |
| Q4 FY2020 | 31 Dec 2020 | 16.19 | 163.65B | 10.11B |
| Q3 FY2020 | 30 Sept 2020 | 13.75 | 151.60B | 11.03B |
| Q2 FY2020 | 30 Jun 2020 | 14.15 | 146.39B | 10.34B |
| Q1 FY2020 | 31 Mar 2020 | 16.48 | 93.38B | 5.67B |
| Q4 FY2019 | 31 Dec 2019 | 18.01 | 96.66B | 5.37B |
| Q3 FY2019 | 30 Sept 2019 | 24.43 | 88.94B | 3.64B |
| Q2 FY2019 | 30 Jun 2019 | 23.30 | 74.55B | 3.20B |
| Q1 FY2019 | 31 Mar 2019 | 24.66 | 72.39B | 2.94B |
| Q4 FY2018 | 31 Dec 2018 | 21.81 | 65.98B | 3.03B |
| Q3 FY2018 | 30 Sept 2018 | 22.87 | 64.20B | 2.81B |
| Q2 FY2018 | 30 Jun 2018 | 23.59 | 59.74B | 2.53B |
| Q1 FY2018 | 31 Mar 2018 | 28.66 | 80.12B | 2.80B |
| Q4 FY2017 | 31 Dec 2017 | 26.57 | 62.85B | 2.37B |
| Q3 FY2017 | 30 Sept 2017 | 38.64 | 87.90B | 2.28B |
| Q2 FY2017 | 30 Jun 2017 | 36.55 | 84.65B | 2.32B |
| Q1 FY2017 | 31 Mar 2017 | 42.49 | 80.60B | 1.90B |
| Q4 FY2016 | 31 Dec 2016 | 38.77 | 70.42B | 1.82B |
| Q3 FY2016 | 30 Sept 2016 | 46.46 | 67.98B | 1.46B |
| Q2 FY2016 | 30 Jun 2016 | 53.00 | 72.95B | 1.38B |
| Q1 FY2016 | 31 Mar 2016 | 46.18 | 55.25B | 1.20B |
| Q4 FY2015 | 31 Dec 2015 | 46.58 | 52.78B | 1.13B |
| Q3 FY2015 | 30 Sept 2015 | 46.24 | 35.80B | 774.19M |
| Q2 FY2015 | 30 Jun 2015 | 44.54 | 34.20B | 767.94M |
| Q1 FY2015 | 31 Mar 2015 | 42.33 | 30.06B | 710.09M |
| Q4 FY2014 | 31 Dec 2014 | 24.51 | 20.84B | 850.39M |
| Q3 FY2014 | 30 Sept 2014 | 16.78 | 14.27B | 850.63M |
| Q2 FY2014 | 30 Jun 2014 | 17.92 | 13.06B | 728.77M |
| Q1 FY2014 | 31 Mar 2014 | 16.57 | 12.44B | 750.87M |
| Q4 FY2013 | 31 Dec 2013 | 16.26 | 10.79B | 663.57M |
| Q3 FY2013 | 30 Sept 2013 | 20.02 | 12.23B | 610.63M |
| Q2 FY2013 | 30 Jun 2013 | 14.30 | 8.25B | 576.85M |
| Q1 FY2013 | 31 Mar 2013 | 12.47 | 6.86B | 550.40M |
| Q4 FY2012 | 31 Dec 2012 | 7.80 | 3.78B | 484.64M |
| Q3 FY2012 | 30 Sept 2012 | 6.87 | 2.85B | 414.60M |
| Q2 FY2012 | 30 Jun 2012 | 4.43 | 1.72B | 389.59M |
| Q1 FY2012 | 31 Mar 2012 | 4.38 | 1.58B | 361.82M |
| Q4 FY2011 | 31 Dec 2011 | 4.79 | 1.68B | 350.94M |
| Q3 FY2011 | 30 Sept 2011 | 4.68 | 1.63B | 349.03M |
| Q2 FY2011 | 30 Jun 2011 | 6.61 | 3.13B | 472.76M |
| Q1 FY2011 | 31 Mar 2011 | 5.71 | 3.19B | 558.68M |
| Q4 FY2010 | 31 Dec 2010 | 5.80 | 3.38B | 582.08M |
| Q3 FY2010 | 30 Sept 2010 | 4.14 | 2.83B | 683.82M |
| Q2 FY2010 | 30 Jun 2010 | 5.08 | 2.73B | 538.25M |
| Q1 FY2010 | 31 Mar 2010 | 7.66 | 3.39B | 442.62M |
| Q4 FY2009 | 31 Dec 2009 | 6.01 | 3.52B | 586.08M |
| Q3 FY2009 | 30 Sept 2009 | — | 6.02B | — |
| Q2 FY2009 | 30 Jun 2009 | — | 8.36B | — |
| Q1 FY2009 | 31 Mar 2009 | — | 9.52B | — |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:P/E ratio,Market cap,ROE (return on equity),Debt to equity,Current ratio,All ratios
Common questions about Genmab A's P/S ratio
Source: Financial Modeling Prep